IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group
Xu Lan-ping; Huang Xiao-jun
关键词Hematopoietic Stem Cell Transplantation Registration Unrelated Haploidentical
刊名CHINESE MEDICAL JOURNAL
2011-08-20
DOI10.3760/cma.j.issn.0366-6999.2011.16.027
124期:16页:2548-2555
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; BONE-MARROW-TRANSPLANTATION ; DONOR LYMPHOCYTE INFUSION ; RISK ACUTE-LEUKEMIA ; HEMATOLOGICAL MALIGNANCIES ; DEPLETION ; PROPHYLAXIS ; OUTCOMES ; RELAPSE ; GVHD
英文摘要

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has three decades history in China. During these periods, the number of HSCT has been increasing, donor and stem cell sources were expanded, indication of diseases and patients for HSCT extended. Forty-two HSCT units offered their data 1-6 times from July 2007 to June 2010. The annual increase rates were 8.8% to 10.8%. Matched sibling donor is 41%, mismatched related/haploidentical donor is 24%, unrelated volunteer donor is 16%, and umbilical cord blood is 2%. The indications of major disease entities are acute myeloid leukemia (AML, 35%), acute lymphobastic leukemia (ALL, 25%), chronic myeloid leukemia (CML, 21%), and myelodysplastic syndrome (MDS, 8%). The different opinions on the indication of HSCT were supported by some trials, matched/haploidentical HSCT fit for middle or high risk ALL and AML in first complete remission (CR1), the international prognosis score system (IPSS) - middle-II/high risk MDS, CML in advanced stage and so on, when patients have no matched sibling donor. In the Peking University Institute of Hematology, Peking University People′s Hospital, haploidentical HSCT has received a comparable result to matched simbling donor HSCT and unrelated matched donor HSCT; we suggest haploidentical donor might be a routine alternative donor for high-risk patents who need an urgent HSCT without matched related donor in special center. Chin Med J 2011;124(16):2548-2555

语种英语
WOS记录号WOS:000294584200027
项目编号IRT0702 ; 200802027
资助机构Program for Innovative Research Team in University ; Ministry of Health of China
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52658
专题北京大学第二临床医学院_血液科
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Xu Lan-ping,Huang Xiao-jun. Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group[J]. CHINESE MEDICAL JOURNAL,2011,124(16):2548-2555.
APA Xu Lan-ping,&Huang Xiao-jun.(2011).Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group.CHINESE MEDICAL JOURNAL,124(16),2548-2555.
MLA Xu Lan-ping,et al."Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group".CHINESE MEDICAL JOURNAL 124.16(2011):2548-2555.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xu Lan-ping]的文章
[Huang Xiao-jun]的文章
百度学术
百度学术中相似的文章
[Xu Lan-ping]的文章
[Huang Xiao-jun]的文章
必应学术
必应学术中相似的文章
[Xu Lan-ping]的文章
[Huang Xiao-jun]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。